AbbVie Inc.: appoints director John M. Carethers

What happened AbbVie Inc filed an 8-K reporting that on Oct 14, 2026 it expanded the size of its Board from 12 directors to 13 directors and appointed Dr. John M. Carethers as a Class II director. The filing says Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and previously was a director of Avantor, Inc.

The filing states that Dr. Carethers was appointed to AbbVie’s Public Policy and Sustainability Committee, that the Board determined he is an “independent director” under section 303A.02 of the New York Stock Exchange Listed Company Manual and AbbVie’s Governance Guidelines and Director Independence Guidelines, and that he will be entitled to compensation as an independent director as disclosed in Exhibit 10.5 to AbbVie’s Quarterly Report on Form 10-Q for the quarterly period ended Mar 31, 2025.

Key details

• Board size expanded from 12 directors to 13 directors on Oct 14, 2026.
• Dr. John M. Carethers appointed as a Class II director and named to the Public Policy and Sustainability Committee.
• Board affirmatively determined Dr. Carethers is independent under section 303A.02 and AbbVie’s governance guidelines.
• Director compensation will follow the terms disclosed in Exhibit 10.5 to AbbVie’s Form 10-Q for the quarter ended Mar 31, 2025.

Why it may matter This Item 5.02 filing covers departure or election of directors, appointment of certain officers, and compensatory arrangements for certain officers and directors. This filing does not show why the insider traded or why the company acted.